Clinical Trials Logo
  1. Home
  2. Angina
  3. NCT00091429

Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine

Angina Clinical Trial

Official title:
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day

Clinical Trial Summary

The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain symptomatic despite daily treatment with the maximum labeled dose of amlodipine (10 mg daily), a calcium channel blocker approved for the treatment of chronic angina. Eligible patients will be randomized to receive ranolazine 1000 mg or placebo twice daily, in addition to a daily dose of 10 mg of amlodipine. Participation in the study will last approximately 3 months.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00091429
Study type Interventional
Source Gilead Sciences
Contact
Status Completed
Phase Phase 3
Start date August 2004
Completion date February 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Withdrawn NCT03134105 - A Wearable EducAtional Intervention to REduce Angina N/A
Completed NCT02832115 - Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention Phase 4
Completed NCT02265796 - Ranolazine Among Unrevascularized Chronic Stable Angina Patients Phase 2
Terminated NCT00221182 - Stem Cell Study for Patients With Heart Disease Phase 1/Phase 2
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Recruiting NCT01214499 - Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina Phase 2
Terminated NCT01285297 - Safety Study of Transmyocardial Revascularization (TMR) With Bone Marrow Aspirate (BMAC) for Angina Reduction N/A
Withdrawn NCT00774891 - Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography N/A
Completed NCT02707783 - Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina
Completed NCT02065102 - Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty N/A
Completed NCT00946725 - To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg Phase 1
Recruiting NCT02439541 - Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy Phase 1/Phase 2
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Withdrawn NCT00657514 - Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Phase 4
Recruiting NCT01361659 - Shockwave Treatment for Advanced Angina in Maastricht N/A
Recruiting NCT05786417 - LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions Phase 4
Withdrawn NCT02507050 - Ivabradine and Post-revascularisation Microcirculatory Dysfunction Phase 4
Active, not recruiting NCT02468960 - Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS) N/A
Completed NCT01086228 - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan N/A